Lode Debrabandere
Directeur/Bestuurslid bij Prolexys Pharmaceuticals, Inc.
Profiel
Lode Debrabandere is currently a Director at Prolexys Pharmaceuticals, Inc. He previously worked as the President, Chief Executive Officer & Director at Osiris Therapeutics, Inc. from 2014 to 2016.
He was also the President, Chief Executive Officer & Director at Elutia, Inc. and a Vice President-Strategic Marketing at Bristol Myers Squibb Co. Dr. Debrabandere holds an MBA and a doctorate from Katholieke Universiteit Leuven.
Actieve functies van Lode Debrabandere
Bedrijven | Functie | Begin |
---|---|---|
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Lode Debrabandere
Bedrijven | Functie | Einde |
---|---|---|
ELUTIA INC. | Algemeen Directeur | 04-06-2018 |
OSIRIS THERAPEUTICS, INC. | Algemeen Directeur | 03-02-2016 |
BRISTOL-MYERS SQUIBB COMPANY | Verkoop & Marketing | - |
Opleiding van Lode Debrabandere
Katholieke Universiteit Leuven | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
ELUTIA INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Osiris Therapeutics, Inc.
Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |